ABT

By Colin Kellaher

Abbott Laboratories on Thursday said the U.S. Food and Drug Administration approved the expanded use of its Proclaim XR spinal-cord-stimulation system to treat painful diabetic peripheral neuropathy.

The Abbott Park, Ill., maker of healthcare products said the system can provide relief to patients with the debilitating complication of diabetes who are in need of alternatives to traditional treatment approaches, such as oral medication.

Abbott said about 34.2 million Americans, or more than 10% of the U.S. population, have diabetes, and that roughly half of adults with diabetes will develop peripheral neuropathy, which may include symptoms such as pain and numbness in the legs, feet and hands. The are currently no disease modifying treatments for diabetic peripheral neuropathy.

The FDA in 2019 approved the Proclaim XR for the treatment of chronic pain.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 26, 2023 09:33 ET (14:33 GMT)

Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Fev 2023 até Mar 2023

Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Mar 2022 até Mar 2023